A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02492789|
Recruitment Status : Completed
First Posted : July 9, 2015
Last Update Posted : September 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumors and Hematologic Malignancy||Biological: INCSHR01210 injection||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||49 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors|
|Study Start Date :||September 1, 2015|
|Actual Primary Completion Date :||March 1, 2019|
|Actual Study Completion Date :||July 5, 2019|
3 dose levels are designed in this study.3 to 6 patients (traditional "3+3" design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle).
Biological: INCSHR01210 injection
Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.
Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study.
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 15 months ]Recommended phase II doses (RP2D) is 200 mg, and the only dose interval to be tested will be once every 4 weeks (Q4W).
- Pharmacokinetics (PK) profile of INCSHR01210 (Tmax) [ Time Frame: Day 1 of cycle 1 ]
- Maximum tolerated dose (MTD) of INCSHR01210 [ Time Frame: 6 months ]
- Incidence of anti-INCSHR01210 antibody in serum [ Time Frame: 15 months ]
- PD-1 receptor occupancy [ Time Frame: 15 months ]
- Duration of response [ Time Frame: 15 months ]
- Objective response rate [ Time Frame: 15 months ]
- Time to progression [ Time Frame: 15 months ]
- Pharmacokinetics (PK) profile of INCSHR01210 (Cmax) [ Time Frame: Day 1 of cycle 1 ]
- Pharmacokinetics (PK) profile of INCSHR01210 (AUC0-28day) [ Time Frame: Day 28 of cycle 1 ]
- Pharmacokinetics (PK) profile of INCSHR01210 (accumulation ratio R) [ Time Frame: Day 28 of each cycle ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02492789
|Austin Hospital/Olivia Newton-John Cancer Research Institute|
|Heidelberg, Victoria, Australia|
|Chris O'Brien Life House|
|Linear Clinical Research Limited|